# Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia

> **NCT02241031** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 250 (estimated)

## Conditions studied

- Hematological Diseases
- Thrombocytopenia

## Interventions

- **BIOLOGICAL:** MPs
- **DRUG:** thrombopoietin (TPO) and interleukin-11

## Key facts

- **NCT ID:** NCT02241031
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-09
- **Primary completion:** 2016-09
- **Final completion:** 2016-12
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2014-09-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02241031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02241031, "Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02241031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*